ReviewThe British journal of general practice : the journal of the Royal College of General Practitioners1996
Who needs antiplatelet therapy?
Review in The British journal of general practice : the journal of the Royal College of General Practitioners, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.BMJ (Clinical research ed.) · 1998Guideline
- Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation.Current drug targets · 2017Review
- Antiplatelet therapy.The British journal of general practice : the journal of the Royal College of General Practitioners · 1996Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of overviews or meta-analyses of randomized clinical trials prepared by the Antiplatelet Trialists' Collaboration were published in the British Medical Journal in January 1994. They demonstrated that prolonged courses of medium-dose aspirin were very effective at preventing both fatal and non-fatal myocardial infarction and stroke in patients at high risk of occlusive vascular disease. The aim of this review is to provide the general practitioner with a practical guide to the use of aspirin in patients at high and low risk of occlusive vascular disease and to discuss appropriate dosages and contraindications to treatment in the light of all the recent evidence.
Indexed as
Identifiers
8983259PMC1239672What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.